Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2026)

Kymera Therapeutics (KYMR) has disclosed Long-Term Investments for 7 consecutive years, with $894.7 million as the latest value for Q1 2026.

  • For Q1 2026, Long-Term Investments rose 186.46% year-over-year to $894.7 million; the TTM value through Mar 2026 reached $894.7 million, up 186.46%, while the annual FY2025 figure was $771.2 million, 112.95% up from the prior year.
  • Long-Term Investments hit $894.7 million in Q1 2026 for Kymera Therapeutics, up from $771.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $894.7 million in Q1 2026 and bottomed at $61.4 million in Q1 2023.
  • Average Long-Term Investments over 5 years is $273.7 million, with a median of $192.4 million recorded in 2024.
  • Year-over-year, Long-Term Investments plummeted 59.68% in 2023 and then soared 489.84% in 2024.
  • Kymera Therapeutics' Long-Term Investments stood at $152.3 million in 2022, then crashed by 59.68% to $61.4 million in 2023, then skyrocketed by 489.84% to $362.2 million in 2024, then skyrocketed by 112.95% to $771.2 million in 2025, then grew by 16.02% to $894.7 million in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $894.7 million, $771.2 million, and $473.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.